Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $253.68 million. The enterprise value is $213.05 million.

Market Cap	253.68M
Enterprise Value	213.05M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, after market close.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

DRUG has 7.04 million shares outstanding. The number of shares has increased by 29.26% in one year.

Current Share Class	7.04M
Shares Outstanding	7.04M
Shares Change (YoY)	+29.26%
Shares Change (QoQ)	+48.42%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.31
P/TBV Ratio	6.31
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 126.15, with a Debt / Equity ratio of 0.00.

Current Ratio	126.15
Quick Ratio	125.59
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-206.95

Financial Efficiency

Return on equity (ROE) is -3.35% and return on invested capital (ROIC) is -5.02%.

Return on Equity (ROE)	-3.35%
Return on Assets (ROA)	-4.93%
Return on Invested Capital (ROIC)	-5.02%
Return on Capital Employed (ROCE)	-4.44%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1,824.60% in the last 52 weeks. The beta is 1.13, so DRUG's price volatility has been higher than the market average.

Beta (5Y)	1.13
52-Week Price Change	+1,824.60%
50-Day Moving Average	38.00
200-Day Moving Average	18.24
Relative Strength Index (RSI)	43.58
Average Volume (20 Days)	69,160

Short Selling Information

The latest short interest is 137,699, so 1.95% of the outstanding shares have been sold short.

Short Interest	137,699
Short Previous Month	172,036
Short % of Shares Out	1.95%
Short % of Float	5.31%
Short Ratio (days to cover)	1.24

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-1.79M
Pretax Income	-3.82M
Net Income	-742,313
EBITDA	n/a
EBIT	-1.79M
Earnings Per Share (EPS)	-$0.15

Full Income Statement

Balance Sheet

The company has $40.24 million in cash and $127,000 in debt, giving a net cash position of $40.11 million or $5.69 per share.

Cash & Cash Equivalents	40.24M
Total Debt	127,000
Net Cash	40.11M
Net Cash Per Share	$5.69
Equity (Book Value)	40.19M
Book Value Per Share	5.75
Working Capital	40.14M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-1.75M
Capital Expenditures	n/a
Free Cash Flow	-1.77M
FCF Per Share	-$0.25

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.26%
Shareholder Yield	-29.26%
Earnings Yield	-0.29%
FCF Yield	-0.70%

Analyst Forecast

The average price target for DRUG is $84.33, which is 134.32% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$84.33
Price Target Difference	134.32%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 0.2:1.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	0.2:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1